Company intelligence / Profile preview
A2A Pharmaceuticals
New York, New York, United States
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Currently in Phase 1 clinical trials for TACC3 inhibitor (A0-252) showing strong safety and efficacy profiles in ovarian cancer, triple-negative breast cancer, and endometrial cancer. The company has progressed to cohort 4 in its Phase 1 trial.
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- Small molecule drugsChemical drugsTargeted protein degraders
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
DAEWOONG PharmaceuticalInsilico MedicineLaxaiNovartisProctor & GambleJohnson & Johnson InnovationJanssen Research & Development
Beyond the preview
Go deeper on A2A Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A2A Pharmaceuticals.